The single image containing only a human face not previously addressed in the literature is employed to estimate body height. The human face especially the facial vertical distribution possesses some important informa...The single image containing only a human face not previously addressed in the literature is employed to estimate body height. The human face especially the facial vertical distribution possesses some important information which strongly correlates with the stature. The vertical proportions keep up relative constancy during the human growth. Only a few facial features such as the eyes, the lip and the chin are necessary to extract. The metric stature is estimated according to the statistical measurement sets and the facial vertical golden proportion. The estimated stature is tested with some individuals with only a single facial image. The performance of the proposed method is compared with some similar methods, which shows the proposal performs better. The experimental results highlight that the developed method estimates stature with high accuracy.展开更多
Copy number variation （CNV） is a type of genetic variation which may have important roles in phenotypic variability and disease susceptibility. To hunt for genetic variants underlying human height variation, we perf...Copy number variation （CNV） is a type of genetic variation which may have important roles in phenotypic variability and disease susceptibility. To hunt for genetic variants underlying human height variation, we performed a genome wide CNV association study for human height in 618 Chinese unrelated subjects using Affymetrix 500K array set. After adjusting for age and sex, we found that four CNVs at 6p21.3, 8p23.3-23.2, 9p23 and 16p12.1 were associated with human height （with borderline significant p value： 0.013, 0.011, 0.024, 0.049; respectively）. However, after multiple tests correction, none of them was associated with human height. We observed that the gain of copy number （more than 2 copies） at 8p23.3-23.2 was associated with lower height （normal copy number vs. gain of copy number： 161.2 cm vs. 153.7 cm, p = 0.011）, which accounted for 0.9% of height variation. Loss of copy number （less than 2 copies） at 6p21.3 was associated with 0.8% lower height （loss of copy number vs. normal copy number： 154.5 cm vs. 161.1 cm, p = 0.013）. Since no important genes influencing height located in CNVs at loci of 8p23.3-23.2 and 6p21.3, the two CNVs may cause the structural rear- rangements of neighbored important candidate genes, thus regulates the variation of height. Our results expand our knowledge of the genetic factors underlying height variation and the biological regulation of human height.展开更多
目的探讨促性腺激素释放激素类似物(GnRHa)联合重组人生长激素(rhGH),单用GnRHa治疗对有月经初潮的特发性中枢性性早熟(ICPP)女童身高的影响。方法回顾性分析2014年1月至2020年12月于徐州医科大学附属徐州儿童医院儿童生长发育门诊就诊7...目的探讨促性腺激素释放激素类似物(GnRHa)联合重组人生长激素(rhGH),单用GnRHa治疗对有月经初潮的特发性中枢性性早熟(ICPP)女童身高的影响。方法回顾性分析2014年1月至2020年12月于徐州医科大学附属徐州儿童医院儿童生长发育门诊就诊76例有月经初潮的ICPP女童为研究对象,根据治疗方案分为治疗对照组(n=22),单用GnRHa治疗组(n=22)和GnRHa联合rhGH治疗组(n=32),随访观察至接近成年终身高(near final adult height,NFAH),比较三组病儿NFAH、身高净生长(ΔHt)、遗传增高(NFAH-遗传身高)。结果对照组、GnRHa组、联合用药组三组就诊基线身高、体质量、身体质量指数(BMI)、骨龄、遗传靶身高差异无统计学意义(P>0.05),随访NFAH分别(158.27±3.63)cm、(159.61±3.91)cm、(162.61±3.34)cm,ΔHt分别(12.66±3.54)cm、(13.49±3.06)cm、(16.79±3.17)cm,遗传增高分别(−2.32±3.82)cm、(0.16±3.46)cm、(3.52±4.62)cm,三组间均差异有统计学意义(P<0.05),其中联合用药组与GnRHa组、对照组比较均差异有统计学意义(P<0.05);GnRHa组和对照组在遗传增高方面差异有统计学意义(P<0.05),在NFAH、ΔHt方面比较均差异无统计学意义(P>0.05)。结论对已有月经初潮的ICPP女孩,GnRHa联合rhGH治疗,可改善NFAH,但需权衡治疗成本及身高获益,临床应谨慎推荐,单用GnRHa治疗不改善NFAH,可改善遗传增高。展开更多
Summary: Ten girls with Turner syndrome were treated with a combination therapy of recombinant human growth hormone (R hGH) and low dose stanozolol for a period of 8 to 36 months. The results showed that when compare...Summary: Ten girls with Turner syndrome were treated with a combination therapy of recombinant human growth hormone (R hGH) and low dose stanozolol for a period of 8 to 36 months. The results showed that when compared with the growth rate before the treatment, the growth rates after treatment with R hGH and stanozolol showed a sustained increase, reaching 9.0±1.9 cm/year during the first year of treatment; the height age increase by 2.5±0.8 years while the bone age increase were 1.0±0.7 years; and the predicted final adult height at the end of the first year of the treatment increased to 149.4±6.1 cm compared to their original mean of 142.8±4.2 cm. We are led to conclude that therapy with R hGH in combination with stanozolol can increase the growth velocity and significantly increase the predicted adult height of children with Turner syndrome.展开更多
文摘The single image containing only a human face not previously addressed in the literature is employed to estimate body height. The human face especially the facial vertical distribution possesses some important information which strongly correlates with the stature. The vertical proportions keep up relative constancy during the human growth. Only a few facial features such as the eyes, the lip and the chin are necessary to extract. The metric stature is estimated according to the statistical measurement sets and the facial vertical golden proportion. The estimated stature is tested with some individuals with only a single facial image. The performance of the proposed method is compared with some similar methods, which shows the proposal performs better. The experimental results highlight that the developed method estimates stature with high accuracy.
基金supported by Natural Science Foundation of China (Nos. 30600364, 30771222, and 30900810)NSFC-Canadian Institutes of Health Research(CIHR) Joint Health Research Initiative Proposal (No.30811120436)+3 种基金NSFC/RGC Joint Research Scheme (No.30731160618)Shanghai Leading Academic Discipline Project (No. S30501)startup fund from Shanghai University of Science and Technologysupported by grants from NIH (Nos. P50AR055081,R01AG026564, R01AR050496, RC2DE020756,R01AR057049, and R03TW008221)
文摘Copy number variation （CNV） is a type of genetic variation which may have important roles in phenotypic variability and disease susceptibility. To hunt for genetic variants underlying human height variation, we performed a genome wide CNV association study for human height in 618 Chinese unrelated subjects using Affymetrix 500K array set. After adjusting for age and sex, we found that four CNVs at 6p21.3, 8p23.3-23.2, 9p23 and 16p12.1 were associated with human height （with borderline significant p value： 0.013, 0.011, 0.024, 0.049; respectively）. However, after multiple tests correction, none of them was associated with human height. We observed that the gain of copy number （more than 2 copies） at 8p23.3-23.2 was associated with lower height （normal copy number vs. gain of copy number： 161.2 cm vs. 153.7 cm, p = 0.011）, which accounted for 0.9% of height variation. Loss of copy number （less than 2 copies） at 6p21.3 was associated with 0.8% lower height （loss of copy number vs. normal copy number： 154.5 cm vs. 161.1 cm, p = 0.013）. Since no important genes influencing height located in CNVs at loci of 8p23.3-23.2 and 6p21.3, the two CNVs may cause the structural rear- rangements of neighbored important candidate genes, thus regulates the variation of height. Our results expand our knowledge of the genetic factors underlying height variation and the biological regulation of human height.
文摘目的探讨促性腺激素释放激素类似物(GnRHa)联合重组人生长激素(rhGH),单用GnRHa治疗对有月经初潮的特发性中枢性性早熟(ICPP)女童身高的影响。方法回顾性分析2014年1月至2020年12月于徐州医科大学附属徐州儿童医院儿童生长发育门诊就诊76例有月经初潮的ICPP女童为研究对象,根据治疗方案分为治疗对照组(n=22),单用GnRHa治疗组(n=22)和GnRHa联合rhGH治疗组(n=32),随访观察至接近成年终身高(near final adult height,NFAH),比较三组病儿NFAH、身高净生长(ΔHt)、遗传增高(NFAH-遗传身高)。结果对照组、GnRHa组、联合用药组三组就诊基线身高、体质量、身体质量指数(BMI)、骨龄、遗传靶身高差异无统计学意义(P>0.05),随访NFAH分别(158.27±3.63)cm、(159.61±3.91)cm、(162.61±3.34)cm,ΔHt分别(12.66±3.54)cm、(13.49±3.06)cm、(16.79±3.17)cm,遗传增高分别(−2.32±3.82)cm、(0.16±3.46)cm、(3.52±4.62)cm,三组间均差异有统计学意义(P<0.05),其中联合用药组与GnRHa组、对照组比较均差异有统计学意义(P<0.05);GnRHa组和对照组在遗传增高方面差异有统计学意义(P<0.05),在NFAH、ΔHt方面比较均差异无统计学意义(P>0.05)。结论对已有月经初潮的ICPP女孩,GnRHa联合rhGH治疗,可改善NFAH,但需权衡治疗成本及身高获益,临床应谨慎推荐,单用GnRHa治疗不改善NFAH,可改善遗传增高。
文摘Summary: Ten girls with Turner syndrome were treated with a combination therapy of recombinant human growth hormone (R hGH) and low dose stanozolol for a period of 8 to 36 months. The results showed that when compared with the growth rate before the treatment, the growth rates after treatment with R hGH and stanozolol showed a sustained increase, reaching 9.0±1.9 cm/year during the first year of treatment; the height age increase by 2.5±0.8 years while the bone age increase were 1.0±0.7 years; and the predicted final adult height at the end of the first year of the treatment increased to 149.4±6.1 cm compared to their original mean of 142.8±4.2 cm. We are led to conclude that therapy with R hGH in combination with stanozolol can increase the growth velocity and significantly increase the predicted adult height of children with Turner syndrome.
